SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Barry Greene to its board of directors. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. He is currently president and chief operating officer of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), a leader in RNAi therapeutics. The appointment increases Ambrx's board membership to six. "Barry joins Ambrx's board at a very exciting time for the company with our continued development of a robust pipeline and establishment of collaborations with pharmaceutical and biotech companies worldwide, including those in the emerging Chinese market," said Lawson Macartney, Ph.D., chief executive officer of Ambrx. "Barry's expertise in strategy and operations with growth companies will be a welcome addition by our directors and company executives. Our position is to build the most dominant, diverse pipeline of biotherapeutics, including antibody-drug conjugates (ADCs) with the most advanced set of technology tools, including our Protein Medicinal Chemistry™." Prior to joining Alnylam in 2003, Mr. Greene was general manager of oncology at Millennium Pharmaceuticals Inc. He focused on global strategy and execution for Millennium's oncology business to guide near- and long-term research, development and commercialization and was involved in the successful approval and launch of VELCADE® (bortezomib). Earlier, he was vice president of strategic integration with responsibility for the AstraZeneca North America post-merger integration and vice president of marketing and customer services for AstraZeneca. Prior to his work with AstraZeneca, he was a partner with Andersen Consulting, where he was responsible for the pharmaceutical and biotechnology marketing and sales practice. Mr. Greene holds a bachelor of science degree in industrial engineering from the University of Pittsburgh. About AmbrxAmbrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including ADCs, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. In addition to its most recent ADC collaborations with Merck, Astellas and Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly and several undisclosed companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas. For additional information, visit www.ambrx.comMedia Contact: David Schull(212) 845-4271 firstname.lastname@example.org SOURCE Ambrx Inc.